1,720,983 research outputs found

    ULTRASTRUCTURAL DEMONSTRATION OF THE NADPH-DIAPHORASE ACTIVITY IN THE PERITUBULAR MYOID CELLS AND FIBROBLASTS OF THE LAMINA PROPRIA OF THE MOUSE SEMINIFEROUS TUBULES

    No full text
    The NOS-related NADPH-diaphorase activity was studied by transmission electron microscopy in the peritubular myoid cells and fibroblasts of normal mouse testis. The reaction product was observed on the membranes of the endoplasmic reticulum, on the Golgi apparatus and nuclear envelope. The peritubular myoid cells and fibroblasts showed similar ultracytochemical features; the intensity of the enzymatic reaction was suggestive of an important role of the NOS/cGMP enzymatic system in these cells. Some hypotheses on the role of NO in the peritubular myoid cells and fibroblasts are proposed

    Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues

    No full text
    Few data are available on the outcome of boys with central precocious puberty (CPP) treated with gonadotropin-releasing hormone (GnRH) analogues. We report on final height, endocrine and exocrine testicular function, and bone mineral density (BMD) in nine males (age 16.7 +/- 1.5 years) treated with GnRH analogues from the age 6.0 +/- 1.8 years for a mean period of 5.6 +/- 2.4 years. The following parameters were evaluated: final height, serum gonadotropin and gonadal steroid levels, spermarche, semen analysis, area and volumetric BMD. Final height(-0.4 +/- 1.1 SDS) was significantly higher than pre-treatment predicted adult height (-2.0 +/- 1.2 SDS) and not significantly different than midparental height (-0.1 +/- 0.8 SDS). Pubertal response of gonadotropins to GnRH test occurred within 1.5 years (mean 0.7 +/- 0.4 years) and spermarche (n = 7) from 0.7 to 3 years (1.8 +/- 0.9 years) after the discontinuation of GnRH analogue therapy. No alteration in semen analysis was found (n = 6, sperm count, 10(6)/ml: 52.0 +/- 18.7; normal motility (%): 49.5 +/- 18.7; atypical morphology (%): 44.5 +/- 11.4). Area and volumetric BMD were not reduced (0.2 +/- 1.0 SDS and -0.1 +/- 0.9 SDS, respectively). Conclusion Long-term treatment with gonadotropin-releasing hormone analogues improves final height in boys with central precocious puberty. Post-therapy data demonstrating normal endocrine and exocrine testicular function support the safety of gonadotropin-releasing hormone analogues on reproductive function. Long-term pharmacological suppression of testicular function in childhood does not impair bone mineral density in late adolescence
    corecore